Their vaccine consisted of six non-mutated melanoma-specific helper peptides (6MHP) and an additional BRAF-V600E peptide combined with two agents that enhance APC function and activation, toll-like receptor 3 (TLR3) agonist and CD40 agonist. The gene discussed is BRAF; the disease is melanoma.